Showing 2081-2090 of 3039 results for "".
- Peeq Waiva Multipurpose Eyelid Cleansing Device Now Availablehttps://modernod.com/news/peeq-waiva-multipurpose-eyelid-cleansing-device-now-available/2481525/Peeq Pro has announced the launch of the Peeq Waiva, an at-home cleansing device designed for daily use to gently and effectively clean eyelids and the skin around the eyes. When used consistently as part of a patient's at-home eye cleansing routine, the device is designed
- American Academy of Optometry Foundation Now Accepting Applications for 2023 Residency Awardshttps://modernod.com/news/american-academy-of-optometry-foundation-now-accepting-applications-for-2023-residency-awards/2481516/The American Academy of Optometry Foundation is accepting requests for applications for its 2023 Residency Awards. Applications must be received by Tuesday, June 1, 2023. Award opportunities include: Douglas Hopkins Primary Care Eye Residency Award&nb
- Shamir Glacier Plus Metaform on Transitions Signature GEN 8 Brown and Grey Now Availablehttps://modernod.com/news/shamir-glacier-plus-metaform-on-transitions-signature-gen-8-brown-and-grey-now-available/2481325/Shamir announced the launch of Shamir Glacier Plus Metaform, a new lens coating that is designed to remove compromises experienced with other lenses. According to Shamir, features of the coating include: Up to 20% thinner & lighter t
- Orasis Pharmaceuticals Submits NDA for Investigational Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopiahttps://modernod.com/news/orasis-pharmaceuticals-submits-nda-for-investigational-novel-eye-drop-candidate-csf-1-for-the-treatment-of-presbyopia/2481315/Orasis Pharmaceuticals announced that it has submitted a new drug application (NDA) to the FDA for investigational CSF-1 (low dose pilocarpine hydrochloride 0.4%). "This NDA submission is a significant milestone for Orasis as we advance CSF-1 towards commercialization and
- Conference and Exhibit Hall Registration Now Open for Vision Expo East 2023 Taking Place March 16-19 in New York Cityhttps://modernod.com/news/conference-and-exhibit-hall-registration-now-open-for-vision-expo-east-2023-taking-place-march-16-19-in-new-york-city/2481282/Conference and Exhibit Hall Registration opens today for
- Aviceda Announces Successful Completion of Key IND Toxicity Milestone with Favorable Safety Profile in Non-Human Primateshttps://modernod.com/news/aviceda-announces-successful-completion-of-key-ind-toxicity-milestone-with-favorable-safety-profile-in-non-human-primates/2481280/Aviceda Therapeutics announced completion of IND-enabling Good Laboratory Practice (GLP) toxicity studies in two species (total of 80 animals) as agreed upon in discussions with the FDA. Cambridge, Massachusetts-based Aviceda, has developed a proprietary nano-technology HALOS&
- Meivertor Single-Handed Upper and Lower Eyelid Eversion Tool Now Availablehttps://modernod.com/news/meivertor-single-handed-upper-and-lower-eyelid-eversion-tool-now-available/2481259/Introduced at the American Academy of Optometry meeting in San Diego, the Meivertor is designed to be a simple solution for an everyday challenge: eversion of the upper eyelid to image the meibomian glands. "Having images of the meibomian glands is important to
- Lori Tierney Joins Johnson & Johnson Vision as President of Americashttps://modernod.com/news/lori-tierney-joins-johnson-johnson-vision-as-president-of-americas/2481184/Johnson & Johnson Vision announced that Lori Tierney has joined the company as President of Americas. In this critical leadership role, Ms. Tierney will have full accountability for shaping the strategy and driving industry-leading growth of the vision care portfolio in both North America and
- First Dry Eye Disease Education Initiative Event from World Council of Optometry and Alcon Set for November 8https://modernod.com/news/first-dry-eye-disease-education-initiative-event-from-world-council-of-optometry-and-alcon-set-for-november-8/2481153/The
- Amydis Enrolls First Participants in PROBE, a Phase 1/2a Trial Evaluating a Novel Retinal Tracer in People with Amyotrophic Lateral Sclerosis or Parkinson’s Diseasehttps://modernod.com/news/amydis-announces-enrollment-of-first-participants-in-probe-a-phase-12a-trial-evaluating-a-novel-retinal-tracer-in-people-with-amyotrophic-lateral-sclerosis-or-parkinsons-disease/2481109/Amydis announced dosing of the first patients in the company’s phase 1/2a trial evaluating AMDXP-2011P, a proprietary small molecule retinal imaging agent “retinal tracer” targeting deposits of alpha synuclein (ASYN) and the TAR DNA-binding protein 43 (TDP-43) in patients w